KRAS and ovarian cancer: In the largest ever study with a total of 140,012 human subjects, the KRAS LCS6 variant did not increase the risk of ovarian cancer or breast cancer, regardless of the BRAC1/2 status; null results were also obtained for associations with overall survival for ovarian cancer, breast cancer, and all other previously reported associations for these cancers46.